A novel series of HDACinhibitors demonstrating classI and IIb subtype selectivity have been identified using a scaffold-hopping strategy. Several designed compounds showed better selectivity for classI and IIb over class IIa HDAC isoforms comparing to the FDA approved HDAC targeting drug SAHA. A representative lead compound 22 bearing a biphenyl moiety demonstrated promising classI and IIb HDAC